Design of fatty acid conjugates for dermal delivery and topical therapeutics

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 23, Issue 1, 2006, Pages 67-87

  Sintov, Amnon ^a   Ben Shabat, Shimon ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Penetration enhancer; Polyunsaturated fatty acids; Prodrugs; Skin permeability; Topical drugs; Transdermal drug delivery

Indexed keywords

ACICLOVIR; ADIPIC ACID; ALKANONE; CARBOXYLIC ACID; DECANOIC ACID; DICARBOXYLIC ACID; DICLOFENAC; DOPAMINE; FATTY ACID; INDOMETACIN; ISOPRENALINE; KETOPROFEN; LAURIC ACID; LEVODOPA; LIDOCAINE; LINOLEIC ACID; MYRISTIC ACID ISOPROPYL ESTER; NALTREXONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OCTANOIC ACID; OLEIC ACID; POLYUNSATURATED FATTY ACID; PRODRUG; PROPYLENE GLYCOL; SATURATED FATTY ACID; SEBACIC ACID; SUCCINIC ACID; UNINDEXED DRUG; UNSATURATED FATTY ACID;

ANTIINFLAMMATORY ACTIVITY; CELL DAMAGE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG SAFETY; EPIDERMIS CELL; HUMAN; HYDROPHILICITY; MEDICAL RESEARCH; NONHUMAN; REVIEW; SKIN DISEASE; SKIN IRRITATION; SKIN PENETRATION; SKIN PERMEABILITY;

EID: 33745056744     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v23.i1.20     Document Type: Review

References (79)

1. Blank, IH. penetration of low-molecular-weight alcohols into skin. I. Effect of concentration of alcohol and type of vehicle. J Invest Dermatol. 1964;43:415-20.
2. Sintov, AC, Shapiro, L. New microemulsion vehicle facilitates percutaneous penetration in vitro and cutaneous drug bioavailability in vivo. J Control Release. 2004;95:173-83.
3. Kreilgaard, M, Kemme, MJB, Burggraaf, J, Schoemaker, RC, Cohen, AF. Influence of a microemulsion vehicle on cutaneous bioequivalence of a lipophilic model drug assessed by microdialysis and pharmacodynamics. Pharm Res. 2001;18:593-99.
4. Kearns, GL, Heacook, J, Daly, SJ, Singh, H, Alander, SW, Qu, S. Percutaneous lidocaine administration via a new iontophoresis system in children: tolerability and absence of systemic bioavailability. Pediatrics. 2003;112:578-82.
5. Burr, GO, Burr, MM. A new deficiency disease produced by the rigid exclusion of fat from the diet. J Biol Chem. 1929;82:345-67.
6. Burr, GO, Burr ,MM. On the nature and role of the fatty acids essential in nutrition. J Biol Chem. 1930;86:587-621.
7. Hansen, AE, Haggard, ME, Boelesche, AN, Adam, D, Wiese, HF. Essential fatty acids in infants nutrition III. Clinical manifestations of linoleic acid deficiency. J Nutr. 1958;66:565-76.
8. Lowe, NJ, DeQuoy, PR. Linoleic acid effects on epidermal DNA synthesis and cutaneous prostaglandin levels in essential fatty acid deficiency. J Invest Dermatol. 1978;70:200-03.
9. Horrobin, DF. Essential fatty acids in clinical dermatology. J Am Acad Dermatol. 1989;20:1045-53.
10. Wright, S. Essential fatty acids and the skin. Br J Dermatol. 1991;125:503-15.
11. Bowser, PA, Nugteren, DH, White, RJ, Houtsmuller, UM, Prottey, C. Identification, isolation and characterization of epidermal lipids containing linoleic acid. Biochim Biophys Acta. 1985;834:419-28.
12. Bouwstra, JA, Gooris, GS, Dubbelaar, FE, Weerheim, A, Ijzerman, AP, Ponec, M. Role of ceramide. 1 in the molecular organization of the stratum corneum lipids. J Lipid Res. 1998;39:186-96.
13. Ponec, M, Weerheim, A, Lankhorst, P, Wertz, P. New acylceramide in native and reconstructed epidermis. J Invest Dermatol. 2003;120:581-88.
14. Hill, JR, Wertz, PW. Molecular models of the intercellular lipid lamellae from epidermal stratum corneum. Biochim Biophys Acta. 2003;1616:121-26.
15. Miller, CC, McCreedy, CA, Jones, AD, Ziboh, VA. Oxidative metabolism of dihomo-γ-linolenic acid by guinea pig epidermis: evidence of generation of anti-inflammatory products. Prostaglandins. 1988;35:917-39.
16. Ziboh, VA, Cho, Y, Mani, I, Xi, S. Biological significance of essential fatty acids/prostanoids/lipoxygenase-derived monohydroxy fatty acids in the skin. Arch Pharm Res. 2002;25:747-58.
17. Chung, S, Kong, S, Seong, K, Cho, Y. γ-Linolenic acid in borage oil reverses epidermal hyperproliferation in guinea pigs. J Nutr. 2002;132:3090-97.
18. Aungst, BJ, Rogers, NJ, Shefter, E. Enhancement of naloxone penetration through human skin in vitro using fatty acids, fatty alcohols, surfactants, sulfoxides and amides. Int J Pharmaceut. 1986;33:225-34.
19. Walters, KA. Penetration enhancers and their use in transdermal therapeutic systems. In: Hadgraft, J, Guy, RH, editors. Transdermal drug delivery, developmental issues and research initiatives. New York: Marcel Dekker; 1989. p 197-246.
20. nd ed. Boca Raton, FL: CRC; 2005.
21. Buyuktimkin, N, Buyuktimkin, S, Rytting, JH. Chemical means of transdermal drug permeation enhancement. In: Ghosh, TK, Pfister, WR, Yum SI, editors. Transdermal and topical drug delivery systems. Buffalo Grove, IL: Interpharm; 1997. p. 357-475.
22. Finnin, BC, Morgan, TM. Transdermal penetration enhancers: application, limitation, and potential. J Pharm Sci. 1999;88:955-58.
23. Williams, AC, Barry, BW. Chemical penetration enhancement: possibilities and problems. In: Roberts, MS, Walters, KA, editors. Dermal absorption and toxicity assessment. New York: Marcel Dekker; 1998.
24. Aungst, BJ. Structure/effect studies of fatty acid isomers as skin penetration enhancers and skin irritants. Pharm Res. 1989;6:244-47.
25. Aungst, BJ, Blake, JA, Hussain, MA. Contributions of drug solubilization, partitioning, barrier disruption, and solvent permeation to the enhancement of skin permeation of various compounds with fatty acids and amines. Pharm Res. 1990;7:712-18.
26. Santoyo, S, Ygartua, P. Effect of skin pretreatment with fatty acids on percutaneous absorption and skin retention of piroxicam after its topical application. Euro J Pharm Biopharm. 2000;50:245-50.
27. Williams, AC, Barry, BW. Penetration enhancers. Adv Drug Del Rev. 2004;56:603-18.
28. Kandimalla, K, Kanikkannan, N, Andega, S, Singh, M. Effect of fatty acids on the permeation of melatonin across rat and pig skin in-vitro and on the transepidermal water loss in rats in-vivo. J Pharm Pharmacol. 1999;51:783-90.
29. Ongpipattanakul, B, Burnette, RR, Potts, RO, Fracoeur, ML. Evidence that oleic acid exists in a separate phase within stratum corneum lipids. Pharm Res. 1991;8:350-54.
30. Naik, A, Pechtold, LARM, Potts, RO, Guy, RH. Mechanism of oleic acid-induced skin penetration enhancement in vivo in humans. J Control Rel. 1995;37:299-306.
31. Loftsson, T, Gudmundsdóttir, TK, Fridriksdóttir, H, Sigurdaróttir, AM, Thorkelsson, J, Gudmundsson, G, et al. Fatty acids from cod-liver oil as skin penetration enhancers. Pharmazie. 1995;50:188-90.
32. Loftsson, T, Thormar, H, Olafsson, JH, Gunnarsdóttir, TM, Hjaltason, B, Gudmundsson, G. Fatty acid extract from cod-liver oil: activity against herpes simplex virus and enhancement of transdermal delivery of acyclovir in-vitro. Pharm Pharmacol Commun. 1998;4:287-91.
33. Barry, BW. Mode of action of penetration enhancers in human skin. J Control Rel. 1987;6:85-97.
34. Yamada, M, Uda, Y, Tanigawara, Y. Mechanism of enhancement of percutaneous absorption of molsidomine by oleic acid. Chem Pharm Bull. 1987;35:3399-3406.
35. Arellano, A, Santoyo, S, Martín, C, Ygartua, P. Influence of propylene glycol and isopropyl myristate on the in vitro percutaneous penetration of diclofenac sodium from carbopol gels. Eur J Pharm Sci. 1999;7:129-35.
36. Larrucca, E, Arellano, A, Santoyo, S, Ygartua, P. Combined effect of oleic acid and propylene glycol on the percutaneous penetration of tenoxicam and its retention in the skin. Eur J Pharm Biopharm. 2001;52:113-19.
37. Oh, SY, Jeong, SY, Park, TG, Lee, JH. Enhanced transdermal delivery of AZT (zidovudine) using iontophoresis and penetration enhancer. J Control Rel. 1998;51:161-68.
38. Okamoto, H, Muta, K, Hashida, M, Sezaki, H. Percutaneous penetration of acyclovir through excised hairless mouse and rat skin: effect of vehicle and percutaneous penetration enhancer. Pharm Res. 1990;7:64-68.
39. Bendas, B, Schmalfuss, U, Neubert, R. Influence of propylene glycol as cosolvent on mechanisms of drug transport from hydrogels. Int J Pharmaceut. 1995;116:19-30.
40. Squillante, E, Needham, T, Maniar, A, Kislalioglu, S, Zia, H. Codiffusion of propylene glycol and dimethyl isosorbide in hairless mouse skin. Eur J Pharm Biopharm. 1998;46:265-71.
41. Sintov, A, Ze'evi, A, Uzan, R, Nyska, A. Influence of pharmaceutical gel vehicles containing oleic/sodium oleate combinations on hairless mouse skin, a histological evaluation. Eur J Pharm Biopharm. 1999;47:299-303.
42. Touitou, E, Godin, B, Karl, Y, Bujanover, S, Becker, Y. Oleic acid, a skin penetration enhancer, affects Langerhans cells and corneocytes. J Control Rel. 2002;80:1-7.
43. Takahashi, K, Matsumoto, T, Kimura, T, Sakano, H, Mizuno, N, Yata, N. Effect of polyol fatty acid esters on diclofenac permeation through rat skin. Biol Pharm Bull. 1996;19:893-96.
44. Takahashi, K, Sakano, H, Yoshida, M, Numata, N, Mizuno, N. Characterization of the influence of polyol fatty acid esters on the permeation of diclofenac through rat skin. J Control Release. 2001;73:351-58.
45. Okumura, M, Sugibayashi, K, Morimoto, Y. Effect of several enhancers on the skin permeation of water-soluble drugs. Chem Pharm Bull. 1989;37:1375-78.
46. Takahashi, K, Sakano, H, Numata, N, Kuroda, S, Mizuno, N. Effect of fatty acid diesters on permeation of anti-inflammatory drugs through rat skin. Drug Dev Ind Pharm. 2002;28:1285-94.
47. Testa, B. Drug metabolism. In: Wolff ME, Editor. Burger's Medicinal Chemistry and Drug discovery. Vol. 1, 5th ed. New York: Wiley-Interscience; 1995. p. 129-80.
48. Wermuth, CG, Gaignault, JC, Marchandeau, C. Designing prodrugs and bioprecursors. I. Carrier prodrugs. In: Wermuth, CG, editor. The practice of medicinal chemistry, Academic; 1996. p. 671-96,.
49. Bonina, FP, Montenegro, L, Guerrera, F. Naproxen. 1-alkylazacycloalkan-2- one esters as dermal prodrugs: in vitro evaluation. Int J Pharm. 1993;100:99-105.
50. Bonina, F, Santagati, NA, Puglia, C. Ketoprofen. 1-alkylazacycloalkan-2- one esters as dermal prodrugs: in vivo and in vitro evaluations, Drug Dev Ind Pharm. 2003;29:181-90.
51. Rautio, J, Taipale, H, Gynther, J, Vepsalainen, J, Nevalainen, T, Jarvinen, T. In vitro evaluation of acyloxyalkyl esters as dermal prodrugs of ketoprofen and naproxen. J Pharm Sci. 1998;87:1622-28.
52. Mendes, E, Furtado, T, Neres, J, Iley, J, Jarvinen, T, Rautio, J, et al. Synthesis, stability and in vitro dermal evaluation of aminocarbonyloxymethyl esters as prodrugs of carboxylic acid agents. Bioorg Med Chem. 2002;10:809-16.
53. Rautio, J, Nevalainen, T, Taipale, H, Vepsalainen, J, Gynther, J, Pedersen, T, et al. Synthesis and in vitro evaluation of aminoacyloxyalkyl esters of 2-(6-methoxy-2-naphthyl)propionic acid as novel naproxen prodrugs for dermal drug delivery. Pharm Res. 1999;16:1172-78.
54. Rautio, J, Nevalainen, T, Taipale, H, Vepsalainen, J, Gynther, J, Laine, K, et al. Piperazinylalkyl prodrugs of naproxen improve in vitro skin permeation. Eur J Pharm Sci. 2000;11:157-63.
55. Rautio, J, Nevalainen, T, Taipale, H, Vepsalainen, J, Gynther, J, Laine, K, et al. Synthesis and in vitro evaluation of novel morpholinyl- and methylpiperazinylacyloxyalkyl prodrugs of 2-(6-methoxy-2-naphthyl)propionic acid (Naproxen) for topical drug delivery. J Med Chem. 2000;43:1489-94.
56. Bonina, FP, Montenegro, L, de Caprariis, P, Palagiano, F, Trapani, G. In vitro and in vivo evaluation of polyoxyethylene indomethacin esters as dermal prodrugs. J Control Release. 1995;34:223-32.
57. Bonina, FP, Puglia, C, Barbuzzi, T, de Caprariis, P, Palagiano, F, Rimoli, MG, et al. In vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac. Eur J Pharm Sci. 2001;14:123-34.
58. Doh, H-J, Cho, W-J, Yong, C-S, Choi, H-G, Kim, JS, Lee, C-H, et al. Synthesis and evaluation of ketorolac ester prodrugs for transdermal delivery. J Pharm Sci. 2003;92:1008-17.
59. Kim, B-Y, Doh, H-J, Le, TN, Cho, W-J, Yong, C-S, Choi, H-G, et al. Ketorolac amide prodrugs for transdermal delivery: stability and in vitro rat skin permeation studies. Int J Pharm. 2005;293:193-202.
60. Stinchcomb, AL, Swaan, PW, Ekabo, O, Harris, KK, Browe, J, Hammell, DC, et al. Straight-chain naltrexone ester prodrugs: diffusion and concurrent esterase biotransformation in human skin. J Pharm Sci. 2002;91:2571-78.
61. Valiveti, S, Hammell, DC, Paudel, KS, Hamad, MO, Crooks, PA, Stinchcomb AL. In vivo evaluation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs. J Control Release. 2005;102:509-20.
62. Ostacolo, C, Marra, F, Laneri, S, Sacchi, A, Nicoli, S, Padula, C, et al α-Tocopherol pro-vitamins: synthesis, hydrolysis and accumulation in rabbit ear skin. J Control Release. 2004;99:403-13.
63. Beall, HD, Sloan, KB. Transdermal delivery of 5-fluorouracil (5-FU) by. 1-alkylcarbonyl-5-FU prodrugs. Int J Pharm. 1996;129:203-10.
64. Taylor, HE, Sloan, KB.. 1-Alkylcarbonyloxymethyl prodrugs of 5-fluorouracil (5-FU): Synthesis, physicochemical properties, and topical delivery of 5-FU. J Pharm Sci. 1998;87:15-20.
65. Roberts, WJ, Sloan, KB. Topical delivery of 5-fluorouracil (5-FU) by 3-alkylcarbonyloxymethyl-5-FU prodrugs. J Pharm Sci. 2003;92:1028-36.
66. Sloan, KB, Wasdo, S, Ezike-Mkparu, U, Murray, T, Nickels, D, Singh, S, et al. Topical delivery of 5-fluorouracil and 6-mercaptopurine by their alkylcarbonyloxymethyl prodrugs from water: vehicle effects on design of prodrugs. Pharm Res. 2003;20:639-45.
67. Wasdo, SC, Sloan, KB. Topical delivery of a model phenolic drug: alkyloxycarbonyl prodrugs of acetaminophen. Pharm Res. 2004;21:940-46.
68. Thorsteinsson, T, Masson, M, Jarvinen, T, Nevalainen, T, Loftsson, T. Cycloserine fatty acid derivatives as prodrugs: synthesis, degradation and in vitro skin permeability. Chem Pharm Bull (Tokyo). 2002;50:554-57.
69. Ahmed, S, Imai, T, Masaki, O. Evaluation of stereoselective transdermal transport and concurrent cutaneous hydrolysis of several ester prodrugs of propranolol: mechanism of stereoselective permeation. Pharm Res. 1996;13:1524-29.
70. Sintov, AC, Behar-Canetti, C, Friedman, Y, Tamarkin, D. Percutaneous penetration and skin metabolism of ethylsalicylate-containing agent, TU-2100: in-vitro and in-vivo evaluation in guinea pigs. J Control Release. 2002;79:113-22.
71. Munster, U, Nakamura, C, Haberland, A, Jores, K, Mehnert, W, Rummel, S, et al. RU 58841-myristate - prodrug development for topical treatment of acne and androgenetic alopecia. Pharmazie. 2005;60:8-12.
72. Masson, M, Thorsteinsson, T, Sigurdsson, TH, Loftsson, T. Lipophilic metronidazole derivatives and their absorption through hairless mouse skin. Pharmazie. 2000;55:369-71.
73. Ben-Shabat, S, Benisty, R, Wormser, U, Sintov, A. Vitamin DS-based conjugates for topical treatment of psoriasis: Synthesis, antiproliferative activity, and cutaneous penetration studies. Pharm Res. 2005;22:50-7.
74. Ottey, KA, Wood, LC, Grunfeld, C, Elias, PM, Feingold, KR. Cutaneous permeability barrier disruption increases fatty acid synthetic enzyme activity in the epidermis of hairless mice. J Invest Dermatol. 1995;104:401-4.
75. Fluhr, JW, Kao, J, Jain, M, Ahn, SK, Feingold, KR, Elias, PM._Generation of free fatty acids from phospholipids regulates stratum corneum acidification and integrity. J Invest Dermatol. 2001;117:44-51.
76. Kew, S, Wells, S, Thies, F, McNeill, GP, Quinlan, PT, Clark, GT, et al. The effect of eicosapentaenoic acid on rat lymphocyte proliferation depends upon its position in dietary triacylglycerols. J Nutr. 2003;133: 4238-40.
77. Bittiner, SB, Tucker, WF, Cartwrightand I, Bleehen, SS. A double-blind, randomised, placebo-controlled trial of fish oil in psoriasis. Lancet. 1988;1:378-80.
78. Maurice, PD, Allen, BR, Barkley, AS, Cockbill, SR, Stammersand, J, Bather, PC. The effects of dietary supplementation with fish oil in patients with psoriasis. Br J Dermatol. 1987;117: 599-606.
79. Mayser, P, Grimmand, H, Grimminger, F. n-3 Fatty acids in psoriasis. Br J Nutr. 2002;87:S77-82.